Cephalosporin Market Report: Trends, Forecast and Competitive Analysis to 2030

Cephalosporin Trends and Forecast

The future of the global cephalosporin market looks promising with opportunities in the first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin markets. The global cephalosporin market is expected to reach an estimated $17.5 billion by 2030 with a CAGR of 2.8% from 2024 to 2030. The major drivers for this market are growing prevalence of infectious diseases, rise in R&D activities for the development of combination drugs, and increase in funding for the development of antibiotics.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Cephalosporin by Segment

The study includes a forecast for the global cephalosporin by type, route of administration, generation, application, and region.

Cephalosporin Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Branded
• Generic

Cephalosporin Market by Route Of Administration [Shipment Analysis by Value from 2018 to 2030]:

• Intravenous
• Oral

Cephalosporin Market by Generation [Shipment Analysis by Value from 2018 to 2030]:

• First-Generation Cephalosporin
• Second-Generation Cephalosporin
• Third-Generation Cephalosporin
• Fourth-Generation Cephalosporin
• Fifth-Generation Cephalosporin

Cephalosporin Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Respiratory Tract Infection
• Skin Infection
• Ear Infection
• Urinary Tract Infection
• Sexually Transmitted Infection
• Others

Cephalosporin Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Cephalosporin Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cephalosporin companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cephalosporin companies profiled in this report include-

• Allergan
• Bristol-Myers Squibb Company
• F.Hoffmann-La Roche
• GlaxoSmithKline
• Lupin Limited
• Merck & Co
• Novartis International

Cephalosporin Market Insights

Lucintel forecasts that generic is expected to witness higher growth over the forecast period as it is relatively cheaper than branded medicine.

Within this market, third-generation cephalosporin is expected to witness the highest growth as it is employed in the treatment of infectious disease.

APAC will remain the largest region over the forecast period due to elevated occurrence of infectious diseases and a surge in the demand for cephalosporin.

Features of the Global Cephalosporin Market

Market Size Estimates: Cephalosporin market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cephalosporin market size by various segments, such as by type, route of administration, generation, application, and region in terms of value ($B).

Regional Analysis: Cephalosporin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, routes of administration, generation, applications, and regions for the cephalosporin market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cephalosporin market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the cephalosporin market size?

Answer: The global cephalosporin market is expected to reach an estimated $17.5 billion by 2030.

Q2. What is the growth forecast for cephalosporin market?

Answer: The global cephalosporin market is expected to grow with a CAGR of 2.8% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cephalosporin market?

Answer: The major drivers for this market are growing prevalence of infectious diseases, rise in R&D activities for the development of combination drugs and increase in funding for the development of antibiotics.

Q4. What are the major segments for cephalosporin market?

Answer: The future of the cephalosporin market looks promising with opportunities in the first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin markets.

Q5. Who are the key cephalosporin market companies?

Answer: Some of the key cephalosporin companies are as follows:

• Allergan
• Bristol-Myers Squibb Company
• F.Hoffmann-La Roche
• GlaxoSmithKline
• Lupin Limited
• Merck & Co
• Novartis International

Q6. Which cephalosporin market segment will be the largest in future?

Answer: Lucintel forecasts that generic is expected to witness higher growth over the forecast period as it is relatively cheaper than branded medicine.

Q7. In cephalosporin market, which region is expected to be the largest in next 5 years?

Answer: APAC will remain the largest region over the forecast period due to elevated occurrence of infectious diseases and a surge in the demand for cephalosporin.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cephalosporin market by type (branded and generic), route of administration (intravenous and oral), generation (first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin), application (respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?